Shanghai Fosun Pharmaceutical Industrial Development Co.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Shanghai Fosun Pharmaceutical Industrial Development Co. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Shanghai Fosun Pharmaceutical Industrial Development Co.: 2 sponsored US clinical trials, none currently recruiting.
Shanghai Fosun Pharmaceutical Industrial Development Co. sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Plexiform Neurofibroma, with 1 trials.
Mid-pack sponsor footprint
Shanghai Fosun Pharmaceutical Industrial Development Co. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
NCT04954001
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
NCT03690154
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
How the Shanghai Fosun Pharmaceutical Industrial Development Co. early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Plexiform Neurofibroma (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Shanghai Fosun Pharmaceutical Industrial Development Co.: archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Shanghai Fosun Pharmaceutical Industrial Development Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Shanghai Fosun Pharmaceutical Industrial Development Co. page
2 registered trials is a research-attention snapshot, not an endorsement of Shanghai Fosun Pharmaceutical Industrial Development Co. or any single study.
- None of Shanghai Fosun Pharmaceutical Industrial Development Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Plexiform Neurofibroma is the condition Shanghai Fosun Pharmaceutical Industrial Development Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Plexiform Neurofibroma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shanghai Fosun Pharmaceutical Industrial Development Co. pipeline card: 2 registered trials from official public datasets.Report a data error.